Evaluating the promotion of biomechanical changes in osteoarthritis treated with lutikizumab: a systematic review and meta-analysis

Objective To evaluate the effect of lutikizumab intervention on patients with osteoarthritis (OA) and provide an evidence-based reference for the clinical application of lutikizumab intervention in patients with osteoarthritis.Methods Literature databases such as PubMed, Embase, web of science, and the Cochrane Library were searched to collect relevant data on randomized controlled trials (RCTs), clinical trials, and single/double arm non-randomized controlled trials studies of therapy interventions for patients with OA, and meta-analysis was performed using RevMan 5.4.Results A total of 6 randomized controlled studies were included, including 737 patients with osteoarthritis. Meta-analysis showed that compared with the control group, lutikizumab intervention had more gains, IL-α (0.3 mg/kg, Q2W, week2) (MD = -0.67, 95% CI [−1.25,-0.09]; Z = 2.26; p = 0.02), IL-1β (3 mg/kg,Q2W,week2) (MD = -0.58, 95% CI [−1.14, −0.02]; Z = 2.03; p = 0.04) and hsCRP (200 mg,Q2W,week8) (MD = -1.79, 95% CI [−2.09, −1.50]; Z = 11.80; p < 0.00001).Conclusion Reducing the OA process with lutikizumab provides a theoretical basis for further investigation of the function of lutikizumab in patients with OA.IL-1 is not only an inflammatory mediator in osteoarthritis, but also a key molecule connecting biomechanical abnormalities and tissue damage.IL-1 inhibitors precisely regulate the spatiotemporal expression of IL-1, and individualize the biomechanical intervention regimens or combination of multiple interventions to achieve optimal therapeutic effects.